Hertrampf A, Müller H, Menezes J C, Herdling T
Quality Operations, Laboratory for Liquid Products, Merck Serono, Frankfurter Str. 250, 64293 Darmstadt, Germany; Institute for Biotechnology and Biosciences, Instituto Superior Técnico, Universidade de Lisboa, Av. Rovisco Pais, 1049-001 Lisbon, Portugal.
Operations, Laboratory for Process Development, Merck Millipore, Frankfurter Str. 250, 64293 Darmstadt, Germany.
J Pharm Biomed Anal. 2015 Oct 10;114:208-15. doi: 10.1016/j.jpba.2015.05.012. Epub 2015 Jun 1.
Pharmaceutical excipients have an influence on the main requirements for medicinal products (viz., quality, safety and efficacy) but also on their manufacturability. During product lifecycle it may become necessary to introduce minor changes (e.g., to continuously improve it) or major changes in the validated process (e.g., moving it to a new production site, replacing process version or even disruptively changing processing type). Those changes can influence the critical to quality attributes of the product. Therefore, it is important to enhance process understanding to avoid the risk of any significant quality changes. Process analytical technology can support better decision making and risk-management as required in quality by design - viz., by many pharmaceutical regulatory authorities. This study compares the quality of the pharmaceutical excipient sodium carbonate (anhydrous) produced either in a batch or a continuous process. For continuous processing two different production lines were available that differed on the dryer and crystallizer types used. Therefore their influence on critical to quality attributes of sodium carbonate was investigated for each of the three processing alternatives. The overall goal was to identify which of the continuous processes ensures a similar product quality to batch processing. Namely, changes on chemical and physical attributes of the product were investigated with Raman spectroscopy, laser diffraction and X-ray powder diffraction. Principal component analysis, a very common multivariate analysis technique, was applied to extract relevant information from small differences at multiple spectral regions from samples from each process type and from each analytical technique used. Changing processing from batch to continuous improved consistency of certain attributes (e.g., particle size distribution) but affected others. However, the increased process/product knowledge gained can lead to an enhanced control strategy and ensure a similar product quality is obtained from distinct process versions.
药用辅料不仅会影响药品的主要要求(即质量、安全性和有效性),还会影响其可制造性。在产品生命周期内,可能有必要对经过验证的工艺进行微小更改(例如持续改进)或重大更改(例如将其转移到新的生产地点、更换工艺版本甚至颠覆性地改变加工类型)。这些更改可能会影响产品的关键质量属性。因此,增强工艺理解以避免任何重大质量变化的风险非常重要。过程分析技术可以支持更好的决策制定和风险管理,这是许多药品监管机构在质量源于设计中所要求的。本研究比较了分批生产或连续生产的药用辅料无水碳酸钠的质量。对于连续加工,有两条不同的生产线可供选择,它们在使用的干燥器和结晶器类型上有所不同。因此,针对三种加工方式中的每一种,研究了它们对碳酸钠关键质量属性的影响。总体目标是确定哪种连续工艺能确保与分批加工相似的产品质量。具体而言,使用拉曼光谱、激光衍射和X射线粉末衍射研究了产品化学和物理属性的变化。主成分分析是一种非常常见的多元分析技术,用于从每种工艺类型和所使用的每种分析技术的样品在多个光谱区域的微小差异中提取相关信息。从分批加工改为连续加工提高了某些属性(例如粒度分布)的一致性,但也影响了其他属性。然而,所获得的更多的工艺/产品知识可以带来增强的控制策略,并确保从不同的工艺版本中获得相似的产品质量。